HIGHBuilt-inProduct / Revenue mix
82%
CryoStor products
“10-K Item 1A: 'we derived approximately 82%, 80%, and 82% of our revenue from CryoStor products, respectively.'”
BLFS · Concentration risk · 10-K extracted
BioLife Solutions (BLFS) concentration risks
Updated
The most significant concentration BioLife Solutions discloses is CryoStor products at 82%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: BioLife Solutions’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH2
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHBuilt-inGeographic
80%
United States
“10-K Item 1: 'United States| 80| %'”
MEDIUMOutside partyCustomer
29%
top three customers
“10-K Item 1A: 'we derived approximately 29%, 32%, and 29% of our revenue from three customers, respectively.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-26BioLife Solutions' concentration profile centers on a single product line and a single geography, both high-share and structural. CryoStor products generated approximately 82% of revenue in the most recent fiscal year, compared with 80% and 82% in the two preceding years — a consistently high-share reliance on one product family rather than a diversified portfolio. Geographically, the United States accounted for 80% of revenue, also a high-share and structural concentration reflecting where the company's customer base is centered rather than a dependency on any single counterparty. On the customer side, the top three customers together accounted for approximately 29% of revenue in the most recent year, versus 32% and 29% in the two prior years — a medium-share dependency that is meaningfully smaller than the product and geographic concentrations and has held roughly steady rather than trending in either direction. Because the CryoStor and U.S.-revenue concentrations are structural features of the business rather than counterparty-specific dependencies, they are less likely to produce a sudden shock than the customer relationships would be, though any erosion in CryoStor demand specifically would flow through to the great majority of the top line given how little revenue diversification exists outside it.
For the engine’s reasoning on BLFS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Instruments & Supplies
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| BLFS● | BioLife Solutions, Inc. | 2 | 1 | 0 | 3 |
| ANGO | AngioDynamics, Inc. | 2 | 0 | 0 | 2 |
| ATRC | AtriCure, Inc. | 1 | 1 | 1 | 3 |
| ATR | AptarGroup, Inc. | 1 | 1 | 0 | 2 |
| ALGN | Align Technology, Inc. | 1 | 0 | 0 | 1 |
| AVR | Anteris Technologies Global Cor | 1 | 0 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.